// App-Quantinova.ai

86 : Safety and efficacy of filgotinib in a phase 3 trial of patients with active rheumatoid arthritis and inadequate response or intolerance to biologic disease modifying anti-rheumatic drugs

Researchers

Presenter

  • David Walker

Principal Investigators

  • Mark C Genovese

  • Kenneth Kalunian

  • Jacques-Eric Gottenberg

  • Kurt de Vlam

  • Neelufar Mozaffarian

  • Beatrix Bartok

  • Franziska Matzkies

  • Jie Gao

  • Ying Guo

  • Chantal Tasset

  • John S Sundy

  • Tsutomu Takeuchi

Medical Centers

  • Department of Research and Development, Northumbria Healthcare NHS FoundationTrust, Tyne and Wear, UNITED KINGDOM

  • Medicine: Immunology and Rheumatology, Stanford University, Stanford, CA

  • Medicine-Rheumatology, University of California, San Diego, La Jolla, CA

  • Department of Rheumatology, National Reference Center for Systemic Autoimmune Diseases, Université de Strasbourg, Strasbourg, FRANCE

  • Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, BELGIUM

  • Gilead Sciences, Gilead Sciences, Foster City, USA

  • Galapagos NV, Galapagos NV, Mechelen, BELGIUM

  • Division of Thoracic Surgery, Keio University School of Medicine, Tokyo, Japan

Locations

  • United Kingdom

  • United States

  • France

  • Belgium

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Filgotinib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT02873936

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved